Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 6/20 | 0.44 |
| ▸ | BRD4 | O60885 | 11/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185400 | 1.00 | CYP19A1 (0.44) | CYP19A1CCR1BRD4NPC1POLB | |
| SCHEMBL4190413 | 0.90 | CCR1 (0.42) | CYP19A1CCR1BRD4NPC1MAPT | |
| SCHEMBL4343117 | 0.90 | CCR1 (0.42) | CYP19A1CCR1BRD4NPC1MAPT | |
| SCHEMBL4190419 | 0.90 | CCR1 (0.42) | CYP19A1CCR1BRD4NPC1MAPT | |
| SCHEMBL6211946 | 0.85 | CCR1 (0.47) | CYP19A1CCR1BRD4NPC1POLB | |
| SCHEMBL4216929 | 0.84 | ALDH1A1 (0.51) | CCR1NPC1POLBMAPTRAB9A | |
| SCHEMBL4216922 | 0.84 | ALDH1A1 (0.51) | CCR1NPC1POLBMAPTRAB9A | |
| SCHEMBL3201062 | 0.83 | KDM4E (0.45) | CYP19A1CCR1BRD4NPC1POLB | |
| SCHEMBL6214263 | 0.82 | BRD4 (0.58) | BRD4NPC1POLBMAPTRAB9A | |
| SCHEMBL3807614 | 0.82 | BRD4 (0.58) | BRD4NPC1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | claimed |
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064884-A1 | Novel Process 1 | TPX2, UGT1A1, BRIX1 | CYP19A1 249/4885CCR1 258/4885BRD4 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.